STIM Share Price Performance
US$1.50
-2.57 (-63.14%)
65.4% undervalued intrinsic discount
US$4.33
Fair Value
Price US$1.50
AnalystConsensusTarget US$4.33
AnalystLowTarget US$3.00
AnalystHighTarget US$7.00
Fair ValueUS$4.33
Share Pricen/a
Neuronetics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
STIM Community Narratives
AN
Fair Value US$4.33 65.4% undervalued intrinsic discount
Expanding Mental Healthcare Outreach Will Unlock Future Potential
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value US$3 50.0% undervalued intrinsic discount
Clinic Margin Pressures And Cash Burn Will Shape This Mental Health Platform’s Eventual Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$7 78.6% undervalued intrinsic discount
Clinic Network And New Therapies Will Transform Mental Health Treatment Over The Next Decade
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Expanding Mental Healthcare Outreach Will Unlock Future Potential
Key Takeaways Strategic provider programs and operational improvements are enhancing patient conversion, driving higher procedure volumes, and improving operating margins. Expansion into adolescent care and broader market acceptance are creating new revenue streams, supporting sustained multi-year growth and brand differentiation.Read more
86
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
US$4.33
65.4% undervalued intrinsic discount
Fair Value
Profit Margin
12.7%
Future PE
16.98x
Price in 2029
US$5.69
Clinic Margin Pressures And Cash Burn Will Shape This Mental Health Platform’s Eventual Upside
Catalysts About Neuronetics Neuronetics develops and operates NeuroStar TMS systems and Greenbrook mental health clinics that provide device based and drug based treatments for depression and other conditions. What are the underlying business or industry changes driving this perspective?Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$3
50.0% undervalued intrinsic discount
Fair Value
Profit Margin
13.08%
Future PE
11.2x
Price in 2029
US$3.96
Clinic Network And New Therapies Will Transform Mental Health Treatment Over The Next Decade
Catalysts About Neuronetics Neuronetics develops and commercializes NeuroStar TMS systems and operates Greenbrook clinics that provide device based and drug treatments for mental health conditions, including treatment resistant depression. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$7
78.6% undervalued intrinsic discount
Fair Value
Profit Margin
13.36%
Future PE
25.96x
Price in 2029
US$9.33
Trending Discussion
Recently Updated Narratives
AN
STIM: Reset Expectations And Higher Discount Rate Will Support Future Repricing
Fair Value: US$4.33 65.4% undervalued intrinsic discount
7 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Clinic Margin Pressures And Cash Burn Will Shape This Mental Health Platform’s Eventual Upside
Fair Value: US$3 50.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Clinic Network And New Therapies Will Transform Mental Health Treatment Over The Next Decade
Fair Value: US$7 78.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Neuronetics, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 05, 2026
- -0.56
- 48.75%
- -26.15%
- 250.8%
About STIM
- Founded
- 2001
- Employees
- 658
- CEO
- WebsiteView website
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
